Scalper1 News
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock was trading on the Alternet market of the Euronext Paris exchange. The company, however, sold 750,000 more shares than it had announced just a day before, when it upped its planned deal size by 50% from Scalper1 News
Scalper1 News